Identification and enrichment of cell subpopulations
AssigneeAbbvie Stemcentrx LLC
InventorsScott J. Dylla, Marianne Santaguida, Wade C. Anderson
Life of this patent
Estimating the term…
Abstract
Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.
Claims21
1-111. (canceled)
A tumorigenic cell population enriched for expression of at least one tumor initiating cell associated marker (TICAM) selected from CD9, CD13, CD15, CD24, CD26, CD29, CD46, CD49a, CD49b, CD49c, CD49f, CD51, CD54, CD55, CD58, CD63, CD66a, CD66c, CD66c, CD71, CD73, CD81, CD82, CD91, CD98, CD99, CD104, CD105, CD108, CD111, CD130, CD136, CD151, CD155, CD157, CD164, CD166, CD172a, CD186, CD221, CD230, CD262, CD273, CD275, CD295, CD298, CD317, CD318, CD324, CD340, CCR10, c-Met, Eph-B2, Eph-B4, FLOR1, Glut-2, Glypican 5, HER3, IL-20Ra, Integrin a9b1, Integrin b5, LDL-R, Mer, Semaphorin 4B, TROP-2 and Vb9.
Dependencies are inferred from the claim text.